The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Convertible Note | Dead

Total Raised


Last Raised


About Pharmedic

Developer of novel transdermal drug delivery technology. Pharmedic is using this technology to develop a topical drug product for the treatment of erectile dysfunction, a large and poorly served market. The company has achieved proof of principle for erectile dysfunction in three pilot human clinical studies. Strategy is to complete successful Phase II trials on two formulations by third quarter 1996. The compound's core technology has the potential for multiple pharmaceutical products.

Pharmedic Headquarter Location

28101 Ballard Street Unit F

Lake Forest, Illinois, 60045,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

  • When was Pharmedic founded?

    Pharmedic was founded in 1989.

  • Where is Pharmedic's headquarters?

    Pharmedic's headquarters is located at 28101 Ballard Street, Lake Forest.

  • What is Pharmedic's latest funding round?

    Pharmedic's latest funding round is Convertible Note.

  • How much did Pharmedic raise?

    Pharmedic raised a total of $4.7M.

  • Who are the investors of Pharmedic?

    Investors of Pharmedic include Apex Venture Partners and Marquette Venture Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.